Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT: Dolutegravir Intensification in HIV
NCT05351684Phase 2Completed
- Sponsor
- University of Liège
- Start
- Jan 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Liège. Started Jan 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05351684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351684.